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ABSTRACT 
In recent times, additional pathways involved in myometrial regulation and also in the 
action of R[\WRFLQDQGȕ-adrenergic agonists on the myometrium, other than what has 
been known previously has been suggested. Knowledge of other pathways will prove 
useful in designing better therapies for myometrial pathologies. This study was 
therefore aimed at investigating the possibility of other pathways involved in the 
DFWLYLW\RIHLWKHUR[\WRFLQRUDȕ-adrenergic agonists (ritodrine was used in this study) in 
myometrial activity with the aid of metabolomics and bioinformatics. High resolution 
Fourier transform mass spectrometry (HRFTMS), and nuclear magnetic resonance 
(NMR) spectroscopy coupled with functional uterine assays were combined for an 
innovative assessment.  In vitro pharmacological assay of oxytocin (1 nM) and ritodrine 
(0.1 nM) on isolated mice uteri mounted in 3 ml organ baths were performed. Mice 
uteri, treated with oxytocin (OT) or ritodrine (RIT), as well as the physiological buffer 
in which the uterine tissues were immersed, were rapidly collected and analysed using 
HRFTMS, 1HNMR and bioinformatics. Resulting data were analyzed via pair-wise 
FKHPRPHWULF FRPSDULVRQ PRGHOV ZLWK S   FRQVLGHUHG VWDWLVWLFDOO\ VLJQLILFDQW ,Q
addition to previously known metabolites, anandamide, nicotinamide adenine 
dinucleotide, gamma aminobutyric acid and sphingosine were significantly associated 
ZLWK 27¶V DFWLYLW\ ZKLOH D GRZQVWUHDP LQYROYHPHQW RI SURVWDJODQGLQ )1 and 
SKRVSKDWLG\OLQRVLWRO VLJQDOOLQJZDVREVHUYHGZLWK5,7¶V DFWLYLW\7KHVH ILQGLQJV DGGV
evidence to the reports on additional regulation of myometrial activity by these drugs 
and also offers newer pathways for therapeutic manipulation. 
Keywords: Uterus; Oxytocin; Ritodrine; pharmacology; metabolomics 
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Introduction 
7KH XWHUXV KDV EHHQ GHVFULEHG DV µWKH SRRU VLVWHU DPRQJ LVRODWHG WLVVXHV LQ WKH
pharmacRORJLVW¶VDUPDPHQWDULXP¶EHFDXVH LW LVGLIILFXOW WRZRUNZLWK1. This difficulty 
has created gaps in our current understanding of uterine function and associated 
pathologies (e.g. preterm birth). Comprehensive studies on uterine metabolite profiling 
appear to be sparse. The need for increased comprehension of myometrial metabolites 
perturbed during uterine contraction stimulation and/or inhibition is therefore essential 
for the development of effective treatments and early diagnosis of myometrial 
pathologies in a bid to counter prevailing reproductive health issues. The important 
roles played by metabolites in smooth muscle cells cannot be overemphasized. The use 
of new techniques such as metabolomics shows great potential in improving current 
knowledge on uterine functioning and has therefore been employed in this study 
Oxytocin (OT) is a known uterine contraction stimulant and ritodrine (RIT) a ȕ-
adrenergic agonist is a known uterine relaxant, however some molecular and cellular 
mechanisms underlying oxytocin-induced modulation of uterine contractility are not 
completely understood 2. OT is one of the most potent uterotonic agents known and its 
effect on uterine contractility is of major clinical importance. It is known that OT 
generates inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
3 by binding to its 
cell surface transmembrane receptor (OTR).4 Through a cascade of activity, IP3 and 
DAG metabolites independently mediate the release of Ca2+ from intracellular stores 
and promotes myometrial contraction.5 This pathway is considered the major pathway 
that mediates OTR signal after binding with OT and for a long time was considered the 
only pathway.5 However, in recent times reports on new pathways involved in OT 
activity on the myometrium are emerging 6. For instance, it was recently reported that 
OTR activates mitogen-activated protein kinase (MAPK) and the Rho kinase pathways 
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resulting in increased cytosolic phospholipase A2 and subsequently increased 
prostaglandin production via the cyclooxygenase (COX) pathway.7,8 The COX pathway 
specifically COX-2 is also upregulated by MAPK.8,9 On the other hand, RIT, via ß2-
adrenoceptor activation, is known to activate adenosine triphosphate activated 
potassium (KATP) channels and large conductance potassium (BKCa) channels in the 
myometrium through cyclic adenosine monophosphate (cAMP)-dependent 
phosphorylation and/or directly via guanosine triphosphate (GTP) metabolite.10 This 
pathway is considered the major pathway of RIT in myometrial contraction inhibition. 
RIT is occasionally used clinically for myometrial relaxation in preterm labour.11,12 
Metabolites are functional units released within cells in response to signals. 
Measurement of these metabolites therefore can provide an understanding into the basic 
mechanisms of several metabolic actions 13. The key technologies in metabolomics 
include high resolution Fourier transform mass spectrometry (HRFTMS) and 1D/2D- 
nuclear magnetic resonance (NMR).  These technologies enable the detection and 
identification of several spectral features employed in mapping out potentially 
significant metabolites responsible for a number of biological activities 14,15.  Sampling 
during metabolomic analysis measurement can include biofluids and/or tissues and in 
such instances the tissue samples can be used to investigate specific information related 
to the tissue or organ while the study of biofluids projects the metabolic changes that 
have occurred iQ DQ DQLPDO¶V RUJDQV 16. Incorporating metabolomic analysis therefore 
will further aid in the determination of other pathways involved in the activity of RIT or 
OT on the myometrium. The innovative use of metabolomics coupled with 
pharmacological assay has never been applied previously. As a proof of principle 
however, Shah and colleagues (2009) identified a number of proteins (desmoplakin 
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isoform 1, stratifin and thrombospondin 1) as potential preterm birth protein biomarkers 
from cervical vaginal fluids 17.  
In this study, we report the use of pharmacology coupled with metabolomic 
methods for the characterization of mouse myometrial metabolite alterations that have 
occurred in response to OT and RIT. This study also attempts to identify additional 
pathways involved in myometrial regulation that can be manipulated for therapeutic 
purposes. 
 
Materials and methods 
All experiments were carried out in accordance with the Animal Health and Welfare 
(Scotland) Act 2006 and the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals 2002. 
Animals  
Female virgin C57BL/6 strain laboratory mice weighing between 19-25 g were 
employed in this study and obtained from the Biological Procedures Unit of the 
University of Strathclyde, U.K. Mice were maintained in a controlled environment with 
temperatures maintained at 25°C and the room conditioned to 60% relative humidity. 
Mice were also maintained under a 12/12h cycle of light and dark and had free access to 
food and water. Mice in pro-oestrus and oestrus states were selected via microscopic 
smear examination and macroscopic (visual) examination for these experiments. 
Selected animals were euthanized under rising concentration of CO2 and exsanguinated 
before excision of the uterine tissues was performed. A total of four animals were 
employed for each set of experiments. 
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Contractility Experiments  
The dissected uteri were cut into segments of approximately 0.5-0.8 cm in longitudinal 
length, cleaned of extra connective tissues to provide four preparations per mouse. The 
segments were then weighed and subsequently mounted in warmed (37 °C) 3 ml organ 
baths containing normal Krebs-Henseleit physiological solution which was composed 
of; 118.4 NaCl, 25 NaHCO3, 11.1 Glucose, 4.69 KCl, 2.41 MgSO4, 1.18 KH2PO4, 2.5 
CaCl2 (mM) and continuously gassed with carbogen (95% O2, 5% CO2). Tissues were 
loaded with an initial tension of 1 g and equilibrated for 30 min before subsequent run 
of experiments. The differential force and frequency of spontaneous contractions in the 
longitudinal muscle layer were recorded through Grass (FTO3) isometric force 
transducers connected via Quad Bridge modules to a PowerLab 4/20 data acquisition 
system using Chart 3.3 software (AD Instruments, UK) which was used to store and 
analyze acquired data. 
 
Concentration-Response Studies  
A uterine contractile agent (OT) and relaxant (RIT) of known mechanisms of action 
were used in this study. OT (1 nM), and RIT (0.1 nM) were added to the bath 
containing uterine tissues. Single concentrations of OT and RIT were added to the bath 
for 10 min following stable rhythmic spontaneous contractions. Without washing, the 
uterine tissues were collected at the peak of activity and immediately flash frozen in 
liquid nitrogen. Flash freezing was achieved by rapidly lifting the tissues out of the 
organ bath and cutting the threads holding the uterine segments to the transducer and 
tissue holder. The tissues were then placed into cryovials, immediately capped and 
immersed into liquid nitrogen the whole procedure lasting approximately 30 sec. Fast 
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and efficient flash freezing is important as it has been reported that cells/tissues remain 
responsive to their surrounding until physiologic measures are effected to prevent 
responses completely [19].  The buffer (3 ml) was similarly collected placed into pre-
weighed vials and flash frozen. All samples were subsequently stored at -80°C prior to 
further experiments. 
 
Metabolite Extraction  
Materials for Metabolite Extraction  
Deuterated dimethyl sulphoxide (DMSO-d6) and chloroform (CDCl3), HPLC grade 
methanol, HPLC grade dichloromethane, OT, carbachol, RIT, verapamil, potassium 
chloride, dimethyl sulphoxide (DMSO) were purchased from Sigma (U.K.). All drugs 
were prepared as stock solutions in distilled water, except for RIT which was dissolved 
in DMSO. 
Tissue metabolite extraction 
Each flash frozen tissue was homogenized using an ULTRA-TURRAX T8 
homogenizer (IKA®- WERKE GmbH & Co., Germany) in 400 µl methanol (MeOH), 
vortexed for 60 s before being centrifuged using a Force 7 Fisher Scientific UK Limited 
(Leicestershire, UK)  at 13,000 rpm/g for 5 min. The supernatant was collected using a 
micropipette syringe and formed the polar tissue extracts. The residue was extracted 
with 400 µl dichloromethane (DCM), vortexed for 60 s and centrifuged at 13,000 rpm/g 
for 10 mins. The supernatant was also collected and formed the non-polar tissue 
extracts. Wet homogenization combined with direct extraction has been described as 
one of the best methods for metabolite extraction from tissues as it gives one of the best 
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metabolite reproducibility and improves the extraction process [20]. The whole 
procedure was performed in the cold with the aid of dry ice. The time periods employed 
were predetermined from preliminary experiments. The supernatant was collected using 
a micropipette syringe and dried in pre-weighed vials in preparation for further NMR 
and MS measurements.   
 
Extraction of metabolites released into the buffer solution (bath fluids)  
Buffer samples (bath fluids) were freeze-dried and weighed. The dried samples were 
reconstituted with 500 µl of MeOH and vortexed for 1 min. The solution of the mixture 
was pipetted out and centrifuged as previously described. The supernatant was collected 
and named polar fluid extracts. The residue was reconstituted in 600 µl of DCM and 
followed procedures as described for the tissues to form the non-polar fluid extracts. 
Again all procedures were performed in the cold with the aid of dry ice. 
 
MS Data Acquisition  
The MeOH extracts (both tissue and fluid) were separately reconstituted with 100% 
MeOH while the DCM extracts were reconstituted in DCM : MeOH at a ratio of 30:70 
determined from preliminary experiments as suitable for dissolving the non-polar 
extracts obtained in this study. Samples were transferred into auto sampler MS vials 
containing 200 µl inserts for HPLC-MS analysis.  HPLC-High resolution Fourier 
transform mass spectrometry (HRFTMS) analysis was carried out using a Dionex 
UltiMate® 3000 HPLC system (Thermo Fisher Scientific Inc, Hemel Hempstead, UK) 
HPSOR\LQJD[PP&FROXPQDVLOLFD W\SHȝP&$&(+3/&FROXPQ
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(HiChrom Limited, UK)). The column was eluted with a linear gradient of 90% A 
(0.1% v/v formic acid in water) and 10% B (0.1% v/v formic acid in acetonitrile) 
mobile phases with a flow rate of 0.3 µl/min over 0-35 min then 100% B for a further 5-
min isocratic elution, and a return to starting conditions at 40 min for re-equilibration 
for the last 5 min, using up a total of 45 min for the run. MS identification and analysis 
were carried out using a Thermo Scientific Orbitrap-Exactive (Thermo Fisher Scientific 
Inc, Hemel Hempstead, UK) with a 10 µl injection volume and the mass spectrometer 
was operated with UV detection at 254 nm using both positive and negative ion modes.  
Full scan data were collected from 50 to 2000 m/z (mass to charge ratio) with a scan 
time of 0.1 s. Capillary and cone voltages were set at 3.5 kV and 35 V, respectively; 
desolvation and low controlled source temperatures.   
 
HRLC-HRFTMS profiling  
The HRLC-HRFTMS metabolic profiles of polar and non-polar OT- and RIT-treated 
tissues and surrounding bath fluids were analysed before and after drug treatment. The 
resulting data were then pre-processed and analysis was performed with the online 
metabolomic analysis program, XCMS. The raw LC-MS data obtained were first sliced 
into positive and negative ion modes before conversion to mzXML files prior to XCMS 
processing. Identification of metabolites was performed within XCMS online using 
METLIN database. During processing, a novel nonlinear retention time alignment 
process is performed. This is sequentially performed with matched filtration, peak 
detection, and peak matching.18 Statistical determination was also performed at p < 0.05 
for each pairwise comparison of control and drug-treated groups, with p < 0.01 
considered highly significant.  
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HRLC-HRFTMS Data Analysis 
The XCMS peak areas were extracted and imported into the soft independent method of 
class analogy (SIMCA) ±P (version 13.0, Umetrics AB, Umeå, Sweden) for principal 
component analysis (PCA) and orthogonal partial least squares ± discriminant analysis 
(OPLS-DA).  Statistical analyses based on a pairwise comparison of control and treated 
groups were also acquired for the different drugs. Differentially regulated metabolites 
with p-values less than 5% and fold change greater than 150% were considered 
statistically significant and used for subsequent analyses.19,20 Prior to OPLS-DA 
PRGHOOLQJWKHGDWDZHUHQRUPDOL]HGXVLQJFROXPQFHQWULQJDQG3DUHWRVFDOLQJ¥6'
[SD= standard deviation]) before modelling. 20,21 A default sevenfold cross validation 
was performed on the OPLS-DA model to check for model over fitting, and this was 
determined from the diagnostic parameters R2Y (residual sum of squares of all y-
variables) and Q2Y (an estimate of the predictive ability of the model calculated by 
cross validation of all y-variables). For visualization and interpretation the OPLS-DA 
score scatter plots, S plots and loading plots with confidence intervals were used. The 
jack-knifed loading plot was additionally sorted by size in order to separate up- and 
down-regulated metabolites at each end of the plots. 
Bioinformatic analyses were subsequently performed on resulting data using the 
Ingenuity Pathway Analysis (IPA) tool (Ingenuity Systems, Redwood City, CA) for the 
pathways search regulated by the identified metabolites. IPA-Metabolomics is a 
program within IPA that extracts rich pathway information from metabolomics data.  
6WDWLVWLFDO VLJQLILFDQFH ZDV FDOFXODWHG XVLQJ )LVFKHU¶V H[DFW WHVW S LQGLFDWHG D
statistically significant no-random association.  For a given data set, IPA automatically 
generates the pathways that are related to those metabolites. 
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1H-NMR Measurements  
The dried MeOH extracts obtained from both tissue and fluid extraction processes 
described previously, were weighed and reconstituted in DMSO (200 µl) vortexed for 
30 secs and placed in shigemi NMR tubes (5 mm) or capillary NMR inserts for 1D 1H-
NMR measurements while the DCM extracts were weighed and reconstituted in CDCl3 
(200 µl) and similarly placed in shigemi NMR tubes. Presaturated 1H-NMR 
experiments were carried out on a JEOL-LA400 FT-NMR spectrometer system (JEOL 
Ltd, UK) with an AS400 magnet and for 1+XVLQJD3XOVH)LHOG*UDGLHQW³$XWRWXQH´
40TH5AT/FG broadband high sensitivity probe to accept 5 mm tubes. One-dimensional 
1H-proton with presaturation of the residual water resonance NMR spectra were 
obtained using the following parameters; 32k data points, spectral width of 5998.4 Hz, 
an acquisition time of 2.73 s, a relaxation delay of 3.0 s., and pulse width of 5.47 
requiring a 3.85 min total acquisition time.  
 
NMR data pre-processing and analysis  
All NMR data sets were pre-processed using Mnova version 8.1. The imported spectra 
were manually phased, apodized at Gaussian = 1.0, and baseline corrected to Bernstein 
polynomial order fit (order 3). The spectra were binned between į± 9 ppm at bin 
YDOXHRIįSSPZLGWK%LQVUHSUHVHQWLQJWKHUHVLGXDOZDWHUDQGVROYHQWSHDNVZHUH
removed. The total spectra area was then normalized to a total value of 100. This 
yielded a total of 163 and 165 contiguous data for the polar and non-polar datasets 
respectively. The resulting data yielded a 2D matrix (n x d). The resulting data matrix 
was then exported into SIMCA-P software package (version 13.0, Umetrics AB, Umeå, 
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Sweden).  Mean centring was performed before principal component analysis (PCA) 
and OPLS-DA was applied to the datasets.  The biplot was employed for visualisation 
and to add further information on the NMR data. The S-line was also employed to 
provide supporting information on the variables. It is similar to a statistical total 
correlation spectroscopy (STOCSY) 22 and is particularly suitable for spectroscopy data. 
A colour scale is also utilized for analysis which provides information about the 
chemical shifts of the dataset and corresponding metabolites that contribute to the 
differences among groups. Biplots and S-lines derived from the OPLS-DA models are 
shown in Supplementary figure 2. 
 
1H-NMR Profiling 
Superimposed pair-matched 1H-NMR spectra of control versus treated mouse uterine 
tissues and respective bath fluids are presented in Supplementary figure 6A-H. The 
spectral resolution of the one dimensional (1D) spectra and 2D proton correlation 
spectroscopy combined with reported data from the literature 23±30 enabled the 
identification and assignment of different metabolites at varying chemical shift ranges. 
The Fourier induction decays were processed using Mnova v.8.1.  
 A schematic diagram showing the various processes involved in this study is 
shown in Figure 1. 
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Results 
Effect of Oxytocin and Ritodrine on Spontaneous Uterine Contractions 
OT (1 nM) increased the force and frequency of uterine contractions (Fig. 2A and 3A). 
RIT (10-7 M), however decreased contractility of spontaneously contracting tissues (Fig. 
2B and 3B). This process was necessary in order to observe and confirm the effect of 
the drugs on uterine contraction and to observe the effect at the time of tissue collection.  
 
Metabolomic Analyses 
After XCMS processing, 17154 and 9891 variables were acquired for polar (OTTP) and 
non-polar oxytocin treated tissues (OTTNP), respectively while 21340 and 16934 
variables were acquired for polar (OTFP) and non-polar oxytocin treated fluids 
(OTFNP), respectively.  For polar (RITTP) and non-polar (RITTNP) ritodrine-treated 
tissues, 14149 and 32051 variables were respectively acquired, while 23260 and 26770 
variables were acquired for polar (RITFP) and non-polar ritodrine-treated fluids 
(RITFNP), respectively. These numbers included isotopic and adduct ion peaks.  
Pathways common to both OT and RIT were extracted and found to include 
phosphatidylinositol signalling, niacinamide metabolism, cell signalling, DAG 
signalling and glycerophospholipid and catecholamine metabolism (Table 1).   
The OPLS-DA score plots showed distinct separations between the control and treated 
in all experimental groups. A summary of the parameters acquired for prediction and 
separation in the OPLS-DA models are shown in supplementary table 1 and 2. An S-
plot, which varies slightly from a scatter plot was obtained and used to extract 
significant metabolites and to explain the contribution of the variables on the MS data 
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(Fig. 3). From each of these plots, differentially significant metabolites were extracted 
using the jack knifed column plots arranged in descending order with fitted confidence 
intervals. Columns with confidence intervals that did not include 0, were considered 
significant (Supplementary tables 3A for OT and 3B for RIT). 
 
Metabolomic analysis of OT- treated uterine tissues and bath fluids 
Reliable models were derived with OPLS-DA for all OT-treated groups (R2 = 1.0) and 
the predictive ability was satisfactory, Q2 > 0.4 in all cases (Supplementary table 1 and 
2).  The OPLS-DA plots showed distinct separations between all OT groups in this 
study (Fig. 4 placed near here). Several significantly differential metabolites were 
detected to be either downregulated (negative sign) or upregulated (positive sign). Of 
interest were myoinositol (fold change (FC) = 1.980); and DAG (FC = -5.989 and -
1.264 in tissues and fluids respectively. Also detected were nicotinic acid adenine 
dinucleotide phosphate (NADP) (FC = 2.858) and gamma amino butyric acid (GABA) 
(FC = 5.847 and 2.952 in tissues and fluids respectively; tyrosine (FC = 1.395); 
sphingosine (FC = 2.213 and 1.678);  N-arachidonylamine (AEA) (FC = -5.007); 
several glycerophospholipids such as phosphatidylcholine (PC) with FC = 2.175 and 
phosphatidylethanolamine (PE) with FC = -3.937) were also detected on OT-treated 
myometrium (Supplementary table 3A).  These metabolites and corresponding 
pathways derived from the HRFTMS and 1H-NMR are shown in Fig. 5A-D and 6A 
respectively. Myoinositol and DAG signalling were also detected through multivariate 
analysis of 1H-NMR studies (Fig. 5) and biplots (Supplementary figure 2).  
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Metabolomic analysis of RIT- treated uterine tissues and bath fluids 
Reliable predictive models were similarly derived for the OPLSDA for all RIT-treated 
groups (R2 = 1.0; Q2 > 0.4 in most cases) (Supplementary table 1A).  The OPLS-DA 
plots also showed distinct separations between all RIT groups in this study (Fig. 4). 
Several significant differential metabolites were also detected by HRFTMS. Of interest 
were myoinositol (fold change (FC) = -13.582); AEA (FC = 2.479) and prostaglandin 
F1 (PGF1) (FC = 17.764).  Others included tyrosine (FC = 4.078); PC with FC = 15.263 
and PE with FC = 3.265 (Supplementary table 3B).  Significant metabolites and 
corresponding pathways derived from the HRFTMS and 1H-NMR are shown in Fig. 
5A-D right panel and 6B respectively. Multivariate analysis using the S-line plots (Fig. 
6) and biplots (Supplementary figure 2) of metabolites detected by 1H-NMR studies 
(Supplementary figure 1A-H) enabled the detection of significantly correlated 
metabolites and pathways; of interest was adenosine nucleotide (FC= 0.7979) 
associated with cAMP signalling in RIT treatment. 
 
Bioinformatic analysis of OT-treated uterine tissues 
Significant functions associated with OT-treated groups were lipid and carbohydrate 
metabolism, energy production, nucleic acid metabolism and involvement in 
reproductive system function (Figure 7 left panel). Major pathways detected were 
myoinositol and DAG signalling (Fig. 8A-D left panel). Creation of a network of 
interacting and interrelated metabolites and corresponding pathways showed 
phosphatidylinositol, phosphatidylglycerol and sphingosine pathways as significantly 
associated pathways (Fig. 9 left panel). Others included serotonin, nitric oxide (NO) and 
RhoGDI signalling (Fig. 9 left panel).  
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Bioinformatic analysis of RIT- treated tissues  
Significant functions detected were cell signalling, lipid and carbohydrate metabolism, 
energy production, nucleic acid/amino acid metabolism and involvement in 
reproductive system function (Figure 7 right panel). Pathways detected for RIT included 
myoinositol downregulation, DAG and phosphate signalling as major pathways (Fig. 
8A ± D right panel). A network of interacting metabolites and pathways showed cAMP-
mediated signalling, protein kinase and G-protein receptor signalling to be primarily 
involved with RIT ± induced uterine relaxation (Fig. 9 right panel).  
 
Discussion 
The observation in this study that myoinositol and N-arachidonyl amine were among 
the statistically significant metabolites detected in the OT-treated myometrium, 
correlates with previously documented activities reported on OT-induced uterine 
contraction.31±34 Myoinositol is a glucose derivative that functions in several signalling 
pathways one of which is the phosphatidylinositol signalling pathway 35 activated by 
OT in the uterus. Other interesting findings in this study were the detection of NADP, 
GABA and metabolites involved in pyrimidine/purine biosynthesis as well as 
metabolites involved in NO synthesis, some of which had not been previously 
associated with the action of OT on the uterus.  OT has been associated with the 
inhibition of K+-stimulated release of excitatory amino acids (glutamate, aspartate) in 
the supraoptic nerve via an indirect action on the terminals 12 but not in the 
myometrium. In this study, GABA was also found to have been released into the bath 
fluids in the presence of OT. The role of NADP as an alternative second messenger and 
an additional intracellular Ca2+store (besides the action of IP3 on the sarcoplasmic 
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reticulum during uterine contraction) is emerging.36 This NADP component is coupled 
with the neurotransmitter glutamate 37 which was a significant metabolite observed in 
this study). NADP has also been reported to be linked with OT-induced contraction  1 in 
addition to cyclic ADP-ribose acting on ryanodine receptors.10 Another interesting 
finding was the decreased release of DAG from the tissues into the surrounding bath 
fluid observed in response to OT treatment. The simultaneous release of DAG in 
response to OT has been previously reported.38 However, a study showed that inhibition 
of DAG release did not significantly suppress OT activity in the pregnant rat 
myometrium. 38 An implication that multiple mechanisms besides IP3 and DAG exist in 
relation to the activity of oT on the myometrium.3 These observations were similarly 
supported by the results from the 1H-NMR data from the current study.  Another 
interesting finding was the detection of downregulated N-arachidonyl amine (AEA) 
with FC equivalent to -2.337, on OT treatment. AEA activates cannabinoid receptors 
which have been recently found expressed in reproductive tissues.39 Binding of AEA to 
its receptors has been associated with the reduction and increase of intracellular cAMP 
levels, regulation of ion channels and NO generation.40 AEA has been reported to cause 
both stimulatory and inhibitory effects on uterine contractility.41,42  Bioinformatic 
analysis in this study revealed an association of AEA with lipid metabolism during OT 
treatment. AEA was found to be both increased in tissues and decreased in the 
surrounding bath fluids on OT treatment in this study. The lipids sphingosine and 
kynurenic acid were also detected in this study in association with OT activity. A 
relationship between OT, sphingosine and the lysophospholipids has been previously 
described 9 but not in the myometrium. 
Several metabolites were generated from the action of RIT on spontaneous 
uterine activity. Downregulation of prostaglandin E2 (PGE2) in the bath fluid was 
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detected as RIT decreased uterine contractility.  Bioinformatic analysis showed the 
upregulation of adenosine monophosphate (AMP) owing to the presence of 
pyrophosphates and kinases. A significant decrease in the concentration of myoinositol 
in comparison to OT treatment was also observed suggesting a reduction in the 
phosphatidylinositol signalling pathway in the presence of RIT which supports recent 
studies linking cAMP signalling with phosphatidylinositol.43,44 Decreased AEA 
concentration was also detected with RIT treatment. DAG as well as phenylalanine (a 
precursor of the catecholamines) were significantly reduced in relation to RIT 
treatment.  
On examination of the 1H-NMR spectra of polar RIT- treated tissues  and bath 
fluids, the metabolites lactate, leucine, acetate, GABA and glutamate were consistently 
observed while the spectra of the non-polar tissue and bath fluids showed the presence 
of hydroxybutyrate (HB), leucine, lactate, acetate, GABA and adenosine. The detection 
of adenosine suggests the involvement of cAMP with RIT. These findings on RIT 
activity were additionally supported by the OPLS-DA S-plots and biplots on both the 
MS and NMR data which showed separations between RIT treated tissues and controls 
and RIT-treated bath fluids and controls.  
Comparison of the bioninformatic profiles of uterine tissues and surrounding bath 
fluids 
Chemometric and bioinformatic analysis of the HRFTMS data revealed significant 
biologic functions for each group in this study. In OT-treated tissues and bath fluids; 
lipid metabolism, carbohydrate metabolism, energy production and small molecule 
biochemistry were significantly affected; eicosanoid synthesis, incorporation of 
thymidine, and nucleotide synthesis were also significantly related indicating an 
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involvement of OT with these pathways.  In RIT-treated tissues, cell signalling, lipid 
metabolism and small molecule biochemistry were significantly and in RIT-treated 
fluids, carbohydrate metabolism, energy production, small molecule biochemistry and 
lipid metabolism were significantly affected. Of the significant pathways extracted for 
OT-treated tissues, TCA cycle, myoinositol biosynthesis, gluconeogenesis and inositol 
triphosphate biosynthesis were upregulated. While of the significant pathways extracted 
for RIT-treated tissues, a downregulation of myoinositol biosynthesis, upregulation of 
GABA receptor signalling, gluconeogenesis, DAG biosynthesis, prostanoid 
biosynthesis, serotonin synthesis and sphingosine metabolism were observed. In the 
bath fluids however, an upregulation of creatinine phosphate and ceramide/sphingosine 
biosynthesis were observed. Overall, consistent pertubation of glycerophospholipid 
metabolism and lipid metabolism were involved in both relaxation and contraction of 
the uterus in response to drugs suggesting a role for these glycerophospholipids in the 
regulation of uterine contraction.  
Examination of the bioinformaticcnetworks indicated a strong association of OT 
with myoinositol, inositol triphosphate and diacylglycerol. The involvement of other 
pathways such as sphingosine, serotonin and NO were also dominant. Examination of 
the network indicated a strong association of RIT with a G-protein coupled receptor 
(possibly related to cAMP release and activation) and protein kinase A while the 
significant involvement of dopamine and ERK signalling were detected and are 
suggested to be associated with myometrial ß-adrenoceptor activation.  
Conclusion 
The detection of phosphatidylinositol and DAG pathways in connection with the 
activity of OT on the uterus as well as the detection of AMP, adenosine and components 
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involved in the cAMP pathway in connection with the effect of RIT on the uterus 
validates the sensitivity of this method in the detection of metabolites associated with 
drug function. The discovery of the involvement of other metabolites such as 
sphingosine and AEA with the activity of OT and the association of GABA and AEA 
with the activity of RIT provides a knowledge-based hypothesis for further research.  
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Table 1. Significant pathways and metabolites associated with both OT- and RIT-
treated groups 
Metabolic Pathway Metabolite Adducts m/z Rt Fold Change (FC) 
Oxytocin (OT) Ritodrine (RIT) 
Tissue Fluid Tissue          
Fluid 
Phosphatidyl-inositol 
signalling 
Myo-inositol [M+H-H2O]
+ 163.0607 1.75 nd nd -
13.582 
nd 
  163.0608 1.75 nd 1.98 nd nd 
Nicotine/Nicotinamide 
pathway 
Niacinamide [M+H]+ 123.0554 1.80 2.858 nd nd nd 
  123.0554 1.82 nd nd 4.691 nd 
Glycine, serine and 
threonine pathway 
Betaine aldehyde [M+H]+ 102.0915 2.13 nd nd 1.103 3.191 
  102.0914 2.20 -1.332 3.506 nd nd 
Pyridine/Valine/leucine 
biosynthesis 
Norleucine [M+H-H2O]
+ 340.2593 7.32 -2.337 -1.700 nd nd 
  340.2593 7.32 nd nd nd -735.82 
Cell signalling N-methyl 
arachidonoyl amine 
[M+Na]+ 340.2593 7.48 -2.337 -1.700 nd nd 
 340.2593 7.48 nd nd nd -735.82 
Cell signalling DAG (22:5) [M+H-2H2O]
+ 679.5118 8.56 -5.989 -1.264 nd nd 
 DAG isomer  679.5119 12.09 nd nd nd -
24582.825
Lipid metabolism 2-keto palmitic acid [M+NH4]
+ 288.2531 17.63 nd -82.668 nd - 
   288.2531 17.72 nd nd nd -172.505 
Sphingolipid metabolic 
pathway 
Sphingosine [M+H]+ 300.2897 19.03 2.213 1.678 nd nd 
Sphingosine isomer  300.2897 21.31 nd nd 2.525 nd 
29 
 
Glycerophospho-lipid 
Metabolic pathway 
PC(18:2(2E,4E)/0:0) [M+H]+ 520.3403 19.40 nd -
252.938 
nd nd 
  520.3403 19.51 nd nd nd -451.904 
Glycerophospho-lipid 
Metabolism 
PC(O-14:0/2:0) [M+H]+ 496.3401 20.34 2.261 nd nd nd 
  496.3400 20.34 nd nd 2.108 nd 
Glycerophospho-lipid 
Metabolism 
Glycerophospho-N-
oleoyl ethanolamine 
[M+H]+ 480.3089 20.96 2.318 nd nd nd 
 480.3087 21.00 nd nd 2.422 nd 
Glycerophospho-lipid 
Metabolism 
PC(O-
16:1(11Z)/2:0) 
[M+H]+ 522.3559 21.71 2.150 nd nd nd 
  522.3558 21.72 nd nd nd -55.707 
Diacylglycerol 
biosynthesis 
1-hexadecyl 
Lysophosphatidic 
acid 
[M+ACN+H]+ 438.2981 21.76 nd nd 3.027 nd 
 438.2981 21.78 2.867 -2.749 nd nd 
Glycerophospholipid 
Metabolic pathway 
PE(18:0/0:0) [M+H]+ 482.3243 24.84 nd nd 2.175 nd 
  482.3244 24.86 2.037 nd nd nd 
Glycerophospho-lipid 
Metabolic pathway 
PC(P-15:0/0:0) [M+H]+ 466.3294 26.01 3.037 -1.427 nd nd 
  466.3294 26.10 nd nd 2.880 nd 
Diacylglcerol 
biosynthesis 
1-Octadecyl 
Lysophosphatidic 
acid 
[M+ACN+H]+ 466.3294 26.01 3.037 -1.427 nd nd 
 466.3294 26.10 nd nd 2.880 nd 
Steroid biosynthesis Dihydroxyvitamin 
D3 
[M+H]+ 545.3850 26.22 nd -4.637 nd nd 
  545.3851 26.67 nd nd nd -34.181 
Lipid metabolism/ cell 
signalling 
Oleamide [M+H]+ 282.2791 29.31 2.691 2.085 nd nd 
  282.2791 29.54 nd nd 5.242 nd 
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Catecholamine 
biosynthesis 
N-Adenyl-L-
phenylalanine 
[M+ACN+H]+ 536.1659 34.52 nd -3.606 nd nd 
 536.1659 35.04 nd nd nd -15508.47 
DAG =diacylglycerol,; PC= phosphatidylcholine; PE= phosphoethanolamine; PS= 
phosphoserine; PG = phosphoglycerol; TG=triacylglycerol; m/z = mass to charge; Rt = 
Retention time; FC = fold change; PV = p value.  A positive FC value indicates a 
relatively higher metabolite concentration in the treated groups, while a negative value 
is indicative of a relatively lower concentration in the treated groups. 
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Figure 1. Flow chart showing the steps involved in the study. 
 
Figure 2. Representative recordings of the effect of OT (1 nM) (A) and ritodrine RIT 
(0.1 nM) (B) on spontaneously contracting mouse uterine tissues 
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Figure 3. Mean responses (± S.E.M) of the isolated uterus to OT (bottom panel) and 
RIT (top panel) calculated within a 5 min time range. In each panel, (A) Frequency; (B) 
Amplitude of uterine contractions, and (C) the area under the curve. Spontaneous 
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contractions which occurred in the absence of drug were considered as the control (0.0). 
([SHULPHQWVZHUHSHUIRUPHGDWÛ& SFRPSDUHGZLWKWKHFRQWURODQDO\VHG
using the t-test). n = 5 animals. 
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Figure 4 OPLS-DA scatter score plots of differentially synthesized metabolites observed on treatment of the isolated uterus with OT (left 
panel)and RIT (right panel) as determined by HRFTMS. The red circles represent the treated groups while the blue circles represent the controls. 
n = 5 animals 
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Figure 5 S-Plots of differential regulated metabolites with OT (left panel) and RIT (right panel) treatment of the isolated uterine tissues (A-B) 
and the surrounding bath fluid (C-D) as determined by HRFTMS. The green circles represent all metabolites detected for the particular group. 
Significantly regulated metabolites in the control groups are highlighted in blue shapes while those in the treated groups are highlighted in red 
shapes with corresponding m/z values. OTTP = OT-treated polar tissues; OTTNP = OT-treated non-polar tissues; OTFP = OT-treated polar 
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bath fluids; OTFNP = OT-treated non-polar bath fluids. RITTP = RIT-treated polar tissues; RITTNP = RIT-treated nonpolar tissues; RITFP = 
RIT-treated polar bath fluids; RITFNP    =    RIT- -
LQRVLWROVLJQDOOLQJV\VWHPŸ Ligand-
;  = Glycine, serine and threonine metabolism. The key 
metabolites that were perturbed are listed in Table 1. n = 5 animals 
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Figure 6 Differentially regulated metabolites with OT (A) and RIT (B) as determined 
by 
NMR. A positive p[1] value indicates a relatively higher metabolite concentration in 
the treated groups, while a negative value is indicative of a relatively lower 
concentration in the -
inositol signalling system P\RLQRVLWRO Ÿ   /LJDQG-receptor Interaction/Lipid 
Metabolism -Adenylyl-L-phenylalanine); 
; 
Nicotine/Nicotinamide metabolism;  Glycine, serine and threonine metabolism 
(betaine). n= 5 animals 
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Figure 7 Top functions extracted by IPA software that have been perturbed on treatment of the isolated uterus with oxytocin (left panel) and 
RITTT (right panel). Functions associated with OT- and RIT- treated tissues and fluids are shown in A and B above along the x-axis while the ±
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log (p-value) is indicated on the left y-axis. Taller bars are more significant than shorter bars. The orange line is indicative of the cut-off for 
significance p<0.05 (-log = 1.3). n = 5 animals 
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Figure 8 Top canonical pathways for OT (left panel) and RIT (right panel) extracted by IPA bioinformatics software. Pathways associated with 
OT-treated uterine tissues are shown in A while the bath fluids are shown in B. The pathways are displayed along the x-axis. The stacked bar 
charts represent the overlap of the analysis with the canonical pathways. The green bars represent downregulation and the red bars represent 
upregulation. The orange line is indicative of the cut-off for significance p<0.05. n = 5 animals 
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Figure 9 IPA network of top functions and signalling pathways detected on analysis of OT- (left panel) and RIT- (right panel) treated uterine 
tissues. The network displays the interaction and interrelationship between the metabolites detected on drug treatment. The interconnectivities 
were then pulled together into specific biological functions and pathways. FX = function; CP= canonical pathways. 
 
